The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

9-ME-BC

C
Animal replicated
Research chemicalβ-CarbolineSynthetic NootropicMAO-A Inhibitor
RouteOralGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
9-Methyl-β-Carboline / 9-MBC — Synthetic β-Carboline Dopaminergic Nootropic — β-Carboline, Synthetic Nootropic, MAO-A Inhibitor.
Why people use it
Used primarily for cognitive support.
What the evidence supports
β-Carbolines, including 9-ME-BC, are photosensitizers — compounds that absorb UV light and can transfer that absorbed energy to molecular oxygen, generating reactive oxygen species (ROS) including singlet oxygen and superoxide radicals. When photosensitizers are present in skin cells and the skin is exposed to UV radiation (sunlight, tanning beds), the generated ROS can: damage cellular lipids (lipid peroxidation); damage proteins (oxidative protein modification); cause DNA strand breaks and base modifications (photogenotoxicity). The specific concern for 9-ME-BC: documented photosensitizing effects in vitro and for β-carboline compounds as a class; the aromatic ring system absorbs UV efficiently. Community users of 9-ME-BC should take sun protection seriously during use: avoid prolonged direct sun exposure; use broad-spectrum SPF 30+ sunscreen; wear sun-protective clothing; avoid tanning beds entirely. The photosensitivity risk is not simply cosmetic — photosensitizer-induced DNA damage has genotoxic implications with potential long-term consequences.
If you only read one thing

9-ME-BC has the most compelling in vitro dopaminergic pharmacology in the nootropic research space: it stimulates TH (the rate-limiting enzyme in dopamine synthesis), promotes dopaminergic neuron proliferation and neurite outgrowth, upregulates BDNF and GDNF, blocks MPTP→MPP+ neurotoxic conversion, enhances hippocampal cognition in rats, and does all this in multiple independent research groups' hands. The research group that characterized it proposed it for Parkinson's disease drug development. The community uses it for dopaminergic cognitive enhancement and neuroprotection. All of this is compelling, evidence-based in its scope, and entirely in vitro and animal. Zero human clinical trials. And the compound is a MAO-A inhibitor at IC50 = 1 μM — a potent enough MAOI that dietary tyramine from aged cheese, red wine, or cured meats could cause a hypertensive crisis, and concurrent SSRIs could cause serotonin syndrome. The most carefully framed chapter in this reference.

Check interactions →
Evidence reality check
Evidence snapshot
β-Carbolines, including 9-ME-BC, are photosensitizers — compounds that absorb UV light and can transfer that absorbed energy to molecular oxygen, generating reactive oxygen species (ROS) including singlet oxygen and superoxide radicals. When photosensitizers are present in skin cells and the skin is exposed to UV radiation (sunlight, tanning beds), the generated ROS can: damage cellular lipids (lipid peroxidation); damage proteins (oxidative protein modification); cause DNA strand breaks and base modifications (photogenotoxicity). The specific concern for 9-ME-BC: documented photosensitizing effects in vitro and for β-carboline compounds as a class; the aromatic ring system absorbs UV efficiently. Community users of 9-ME-BC should take sun protection seriously during use: avoid prolonged direct sun exposure; use broad-spectrum SPF 30+ sunscreen; wear sun-protective clothing; avoid tanning beds entirely. The photosensitivity risk is not simply cosmetic — photosensitizer-induced DNA damage has genotoxic implications with potential long-term consequences.
From the chapter quick-reference block.
Risk posture
No major flags listed
Review route-specific cautions before use.
Categories
Cognition & Mood
Properties
Not injectable
Evidence
CAnimal replicated
The Pharmacological Profile
9-ME-BC has a multi-target pharmacological profile: (1) MAO-A inhibitor (IC50 = 1 μM) — more potent for MAO-A than MAO-B (IC50 = 15.5 μM); a functional MAOI-A at likely therapeutic doses. (2) DAT substrate — enters dopaminergic neurons via the dopamine transporter, leading to intracellular accumulation in dopaminergic cells. (3) Tyrosine hydroxylase (TH) upregulator — increases expression of TH, the rate-limiting enzyme in dopamine synthesis, in dopaminergic neuron cultures. (4) Neurotrophic factor inducer — upregulates BDNF, GDNF (Artn), TGF-β2, NCAM1 in astrocyte cultures. (5) MPTP→MPP+ oxidation inhibitor — blocks conversion of the parkinsonian neurotoxin precursor MPTP to the active toxin MPP+, preventing dopaminergic neuron death.
The Safety Concerns — Read Before Mechanism
MAOI-A ACTIVITY (MOST CRITICAL): 9-ME-BC inhibits MAO-A at IC50 = 1 μM. MAO-A in the GI tract normally degrades dietary tyramine before it enters systemic circulation. When inhibited: (a) Tyramine reaction — eating aged cheese, red wine, cured meats, beer, soy sauce, or other tyramine-rich foods while taking 9-ME-BC can cause severe hypertensive crisis (BP 220/120+ mmHg), with symptoms including sudden severe headache, chest pain, nausea. Life-threatening. (b) Serotonin syndrome — concurrent use of SSRIs, SNRIs, tramadol, triptans, 5-HTP, tryptophan, or dextromethorphan with 9-ME-BC risks life-threatening serotonin syndrome. PHOTOSENSITIVITY (SECOND SAFETY CONCERN): β-carbolines are photosensitizers — they absorb UV light and can generate reactive oxygen species and DNA damage. Documented in vitro for 9-ME-BC and related compounds. Sun exposure during 9-ME-BC use may increase photosensitive skin reactions and potential UV-activated genotoxicity.
The Evidence Situation
Zero human clinical trials. All evidence is in vitro (cell culture) and animal (primarily rodent). The in vitro evidence is genuinely compelling — multiple independent research groups have documented dopaminergic neuron stimulation, TH upregulation, BDNF/GDNF induction, and MPTP neuroprotection in cell cultures. The Pubmed 22380576 rat study showed hippocampal cognitive enhancement with elevated dopamine and structural dendritic/synaptic proliferation. None of this has been tested in humans. The community is using a compound with remarkable in vitro/animal pharmacology and documented MAO-A inhibitory activity — without any safety or efficacy data from human clinical trials.
Who Researches This Legitimately
The legitimate research context: Parkinson's disease research. 9-ME-BC was proposed for investigation as a neuroprotective agent for dopaminergic neurons because of its MPTP neuroprotection mechanism and TH/BDNF upregulation profile. The Polanski, Gille, Reichmann and Jost research group (Dresden/Germany) produced most of the seminal in vitro characterization. The proposed application: a potential Parkinson's disease therapeutic that might protect dopaminergic neurons from degeneration and even stimulate their recovery. No clinical trial for PD has been conducted.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Adamax
C
Shared goal · cognition

A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.

ARA-290
C
Shared goal · cognition

Engineered EPO-derived tissue-protective peptide that activates innate repair signaling without erythropoietic red-blood-cell stimulation. Human neuropathy data exist; WADA bans it under EPO-related peptide/mimetic rules; the original developer no longer exists.

Cerebrolysin
B
Shared goal · cognition

More Clinical Trial Data Than Almost Anything in this reference. Approved in Over 40 Countries. The Largest Independent RCT Failed Its Primary Endpoint. Every Major Positive Trial Has the Manufacturer's Name in the Author List. Cochrane Says: Low to Very Low Evidence.

Check interactions